Naringenin (Grapefruit Flavanone · CYP3A4 Modulator · Insulin Sensitiser)

CAS No.	480-41-1
Class	Polyphenol · Flavanone · Flavonoid
Source	Citrus paradisi (Grapefruit) fruit and peel; sour orange, tomato skin. Released from naringin (glycoside) by gut microbiota hydrolysis
Claim strength	Moderate
Buy from Herbuno	Naringin 98% Powder (Pomelo) | High-Purity Isolate | Citrus grandis →

Discovery of the grapefruit–drug interaction: Naringenin is the primary aglycone flavanone of grapefruit, released from its glycoside naringin by gut microbiota. The grapefruit–drug interaction — one of the most clinically significant food–drug interactions — was discovered accidentally in 1989 when researchers used grapefruit juice to mask alcohol flavour in a drug study and found it dramatically elevated felodipine blood levels. Naringenin (alongside furanocoumarins) inhibits intestinal CYP3A4 and P-glycoprotein. Dual significance: This is simultaneously a safety concern (for patients on affected medications) and a formulation opportunity — naringenin can enhance bioavailability of poorly absorbed co-administered compounds. Metabolic research: Beyond drug interactions, naringenin activates PPARα in liver tissue and AMPK in skeletal muscle — mechanisms relevant to hepatic fat oxidation, NAFLD management, and insulin sensitisation. Commercial note: Isolated naringenin aglycone is available; naringin (the glycoside) is also commercially produced from grapefruit peel.

---

Evidence for Metabolic Health, Hepatoprotection & Bioavailability Enhancement

Insulin sensitising and metabolic support: Naringenin activates PPARα in liver (increasing fat oxidation) and AMPK in skeletal muscle (increasing glucose uptake). Multiple animal studies document normalisation of blood glucose and plasma lipids. Human data is limited. Claim strength: Moderate (preclinical strong; limited human trial data).

Hepatoprotection and NAFLD: Reduces hepatic fat accumulation, lowers liver enzyme markers of hepatocellular stress, and inhibits hepatic inflammation in rodent NAFLD models and limited human studies. Claim strength: Moderate.

CYP3A4/P-gp modulation — bioavailability enhancement: Naringenin inhibits intestinal CYP3A4 and P-glycoprotein, increasing bioavailability of co-administered CYP3A4 substrates. Clinically significant for grapefruit-sensitive medications. At supplement doses, a formulation opportunity: meaningfully enhances absorption of curcumin, quercetin, and other poorly bioavailable compounds. Claim strength: High (drug interaction); Moderate (bioavailability enhancement application).

Antioxidant and cardiovascular: Reduces LDL oxidation, inhibits platelet aggregation, improves endothelial function. Claim strength: Moderate.

---

Naringenin vs Naringin & Formulator Specification

Aglycone vs glycoside — which to specify: Naringenin aglycone achieves higher and more predictable plasma concentrations. Naringin (glycoside) has slower, more variable absorption via microbiota hydrolysis. For CYP3A4 inhibition applications and metabolic health formulations requiring consistent plasma concentrations, isolated naringenin aglycone is preferred. For venous and capillary applications, naringin at the glycoside level is appropriate.

Drug interaction label copy — mandatory: Naringenin inhibits CYP3A4, significantly increasing blood levels of statins (simvastatin, atorvastatin), calcium channel blockers, immunosuppressants, and certain antivirals. Products containing meaningful naringenin must carry a statement advising individuals on these medications to consult their healthcare provider. This is not a prohibition on product development — it is required precautionary copy.

Synergistic pairs: Hesperidin (complementary citrus bioflavonoid), piperine (combined CYP inhibitors for bioavailability enhancement stacks), quercetin (metabolic health combination), bergamot extract (comprehensive citrus polyphenol lipid support).

---

Frequently Asked Questions — Naringenin

What is the grapefruit–drug interaction and does it apply to naringenin supplements?
The interaction occurs because grapefruit compounds (primarily furanocoumarins, with naringenin contributing) inhibit intestinal CYP3A4, dramatically increasing blood levels of CYP3A4-metabolised drugs. A single glass of grapefruit juice can increase statin blood levels by 2–5 times. Naringenin supplements contribute to this effect. For individuals on statin medications, calcium channel blockers, or immunosuppressants, naringenin supplementation requires medical supervision and this must be on the product label.

Can naringenin enhance the bioavailability of other supplement ingredients?
Yes — CYP3A4 and P-gp inhibition can meaningfully increase bioavailability of curcumin, quercetin, and other compounds. This is also why the same caution applies to medications: naringenin does not distinguish between supplement ingredients and pharmaceutical drugs when inhibiting CYP3A4. Transparent communication and drug interaction label copy are required.

Is naringenin relevant for metabolic and liver health formulations?
Yes — PPARα activation, AMPK stimulation, and anti-NAFLD activity in preclinical models all support metabolic positioning. Evidence is predominantly animal-model-based. Position as supporting healthy metabolic function as part of a healthy lifestyle rather than as treatment for metabolic conditions.

How does dietary grapefruit intake compare to supplement doses?
A medium grapefruit provides approximately 15–50 mg of naringenin equivalents from naringin hydrolysis. Supplement doses studied in metabolic contexts: 100–500 mg/day — 2–10 times typical dietary grapefruit intake. This explains why supplement doses produce effects that regular dietary grapefruit consumption alone may not.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery